# US 2025/0145700 A1 · Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145700 A1
- Document ID: US20250145700A1
- Status: Published application
- Kind: A1
- Application number: 19/018,905
- Filed: 2025-01-13
- Published: 2025-05-08
- Earliest claimed: 2018-10-30
- Assignees: Alexion Pharmaceuticals, Inc.
- Applicants: Alexion Pharmaceuticals, Inc.
- Inventors: Lori VOLLES; Rajendra PRADHAN; Douglas L. SHERIDAN; Marc VALLEE; Xiang GAO
- Web page: https://patentgrep.com/patent/US20250145700A1

## CPC

- C07K 16/18: against material from animals or humans
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided are methods for clinical treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered (or is for administration) subcutaneously according to a particular clinical dosage regimen (i.e., at a particular dose amount and according to a specific dosing schedule). In one embodiment, the patient has previously been treated with eculizumab (Soliris®).

## Claims

### Claim 1

An on-body delivery system (OBDS) comprising 245 mg ravulizumab in a sterile, single use, prefilled cartridge assembly co-packaged with a single-use injector.

### Claim 2 (depends on 1)

The OBDS of claim 1, comprising 245 mg ravulizumab (70 mg/mL) in 50 mM sodium phosphate, 25 mM arginine, 5% sucrose, 0.05% polysorbate 80, and water for injection for subcutaneous administration.

### Claim 3 (depends on 1)

The OBDS of claim 1, wherein the device is electro-mechanical.

### Claim 4 (depends on 1)

The OBDS of claim 1, wherein the injector comprises a 29-gauge needle.

### Claim 5 (depends on 1)

The OBDS of claim 1, wherein the cartridge is a 3.5 mL cartridge.

### Claim 6 (depends on 1)

The OBDS of claim 1, wherein ravulizumab is formulated at a pH of about 7.4.

### Claim 7 (depends on 1)

The OBDS of claim 1, wherein the device is configured for self-administration.

### Claim 8 (depends on 2)

The OBDS of claim 2, wherein the device is electro-mechanical.

### Claim 9 (depends on 2)

The OBDS of claim 2, wherein the injector comprises a 29-gauge needle.

### Claim 10 (depends on 2)

The OBDS of claim 2, wherein the cartridge is a 3.5 mL cartridge.

### Claim 11 (depends on 2)

The OBDS of claim 2, wherein ravulizumab is formulated at a pH of about 7.4.

### Claim 12 (depends on 2)

The OBDS of claim 2, wherein the device is configured for self-administration.

### Claim 13 (depends on 1)

A kit comprising the OBDS of claim 1 and instructions.

### Claim 14 (depends on 13)

The kit of claim 13, wherein the instructions comprise administration schedules.

### Claim 15 (depends on 2)

A kit comprising the OBDS of claim 2 and instructions.

### Claim 16 (depends on 15)

The kit of claim 15, wherein the instructions comprise administration schedules.
